Loading...

Cantel Medical

DB:CI2
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CI2
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The last earnings update was 78 days ago. More info.


Add to Portfolio Compare Print
  • Cantel Medical has significant price volatility in the past 3 months.
CI2 Share Price and Events
7 Day Returns
-2.5%
DB:CI2
3.1%
DE Medical Equipment
-0.2%
DE Market
1 Year Returns
-44.3%
DB:CI2
14.5%
DE Medical Equipment
-10.4%
DE Market
CI2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cantel Medical (CI2) -2.5% 3.2% -17.1% -44.3% 4.8% 153.9%
DE Medical Equipment 3.1% 2.7% 7.3% 14.5% 108.3% 239.6%
DE Market -0.2% -2.1% 4.2% -10.4% 11.1% 10.6%
1 Year Return vs Industry and Market
  • CI2 underperformed the Medical Equipment industry which returned 14.5% over the past year.
  • CI2 underperformed the Market in Germany which returned -10.4% over the past year.
Price Volatility
CI2
Industry
5yr Volatility vs Market

CI2 Value

 Is Cantel Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cantel Medical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cantel Medical.

DB:CI2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:CI2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.9
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.896 (1 + (1- 21%) (8.64%))
0.971
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.97
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.971 * 5.96%)
6.02%

Discounted Cash Flow Calculation for DB:CI2 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cantel Medical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:CI2 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.02%)
2019 16.80 Analyst x1 15.84
2020 105.60 Analyst x3 93.95
2021 152.00 Analyst x1 127.57
2022 177.00 Analyst x1 140.12
2023 207.00 Analyst x1 154.57
2024 229.80 Est @ 11.01% 161.85
2025 247.67 Est @ 7.78% 164.54
2026 261.32 Est @ 5.51% 163.76
2027 271.59 Est @ 3.93% 160.54
2028 279.24 Est @ 2.82% 155.69
Present value of next 10 years cash flows $1,338.44
DB:CI2 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $279.24 × (1 + 0.23%) ÷ (6.02% – 0.23%)
$4,835.65
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,835.65 ÷ (1 + 6.02%)10
$2,696.19
DB:CI2 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,338.44 + $2,696.19
$4,034.63
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,034.63 / 41.52
$97.17
DB:CI2 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:CI2 represents 0.90566x of NYSE:CMD
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.90566x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 97.17 x 0.90566
€88.00
Value per share (EUR) From above. €88.00
Current discount Discount to share price of €60.00
= -1 x (€60.00 - €88.00) / €88.00
31.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Cantel Medical is available for.
Intrinsic value
32%
Share price is €60 vs Future cash flow value of €88
Current Discount Checks
For Cantel Medical to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Cantel Medical's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Cantel Medical's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cantel Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cantel Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CI2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in USD $1.77
NYSE:CMD Share Price ** NYSE (2019-05-17) in USD $66.25
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 36.34x
Germany Market PE Ratio Median Figure of 426 Publicly-Listed Companies 20.24x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cantel Medical.

DB:CI2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:CMD Share Price ÷ EPS (both in USD)

= 66.25 ÷ 1.77

37.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cantel Medical is overvalued based on earnings compared to the DE Medical Equipment industry average.
  • Cantel Medical is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Cantel Medical's expected growth come at a high price?
Raw Data
DB:CI2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 37.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
22.6%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 3.08x
Germany Market PEG Ratio Median Figure of 277 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

DB:CI2 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 37.51x ÷ 22.6%

1.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cantel Medical is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Cantel Medical's assets?
Raw Data
DB:CI2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in USD $15.45
NYSE:CMD Share Price * NYSE (2019-05-17) in USD $66.25
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.25x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.79x
DB:CI2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:CMD Share Price ÷ Book Value per Share (both in USD)

= 66.25 ÷ 15.45

4.29x

* Primary Listing of Cantel Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cantel Medical is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Cantel Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Cantel Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CI2 Future Performance

 How is Cantel Medical expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cantel Medical expected to grow at an attractive rate?
  • Cantel Medical's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Cantel Medical's earnings growth is expected to exceed the Germany market average.
  • Cantel Medical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CI2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CI2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 22.6%
DB:CI2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 6.8%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CI2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CI2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-07-31
2022-07-31
2021-07-31 1,051 2
2020-07-31 998 145 102 5
2019-07-31 922 116 81 5
DB:CI2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-01-31 896 100 74
2018-10-31 885 128 87
2018-07-31 872 126 91
2018-04-30 849 125 91
2018-01-31 823 118 90
2017-10-31 795 113 75
2017-07-31 770 108 71
2017-04-30 742 102 70
2017-01-31 723 97 67
2016-10-31 697 90 64
2016-07-31 663 80 59
2016-04-30 633 77 56

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cantel Medical's earnings are expected to grow significantly at over 20% yearly.
  • Cantel Medical's revenue is expected to grow by 6.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CI2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Cantel Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CI2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-07-31
2022-07-31
2021-07-31 2.59 2.66 2.52 2.00
2020-07-31 2.35 2.50 2.22 5.00
2019-07-31 1.93 1.96 1.90 5.00
DB:CI2 Past Financials Data
Date (Data in USD Millions) EPS *
2019-01-31 1.77
2018-10-31 2.09
2018-07-31 2.18
2018-04-30 2.19
2018-01-31 2.16
2017-10-31 1.81
2017-07-31 1.71
2017-04-30 1.69
2017-01-31 1.61
2016-10-31 1.55
2016-07-31 1.44
2016-04-30 1.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cantel Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cantel Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cantel Medical has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CI2 Past Performance

  How has Cantel Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cantel Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cantel Medical's year on year earnings growth rate has been positive over the past 5 years.
  • Cantel Medical's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Cantel Medical's 1-year earnings growth is negative, it can't be compared to the DE Medical Equipment industry average.
Earnings and Revenue History
Cantel Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cantel Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CI2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 896.25 73.52 272.17 28.68
2018-10-31 884.75 87.13 266.45 26.40
2018-07-31 871.92 90.72 260.69 24.65
2018-04-30 848.57 90.77 253.22 22.58
2018-01-31 823.42 89.51 245.65 20.30
2017-10-31 795.20 75.09 238.35 19.15
2017-07-31 770.16 70.95 233.01 18.37
2017-04-30 741.62 70.21 224.96 17.84
2017-01-31 723.21 66.70 217.25 17.61
2016-10-31 696.67 64.00 208.28 16.19
2016-07-31 662.72 59.47 194.27 15.41
2016-04-30 632.64 56.47 181.81 14.63
2016-01-31 600.44 54.81 171.30 14.10
2015-10-31 577.60 50.55 163.45 14.24
2015-07-31 560.64 47.52 157.80 14.02
2015-04-30 544.08 44.93 150.14 13.73
2015-01-31 521.70 42.79 142.87 12.82
2014-10-31 504.37 42.77 136.81 12.10
2014-07-31 488.75 42.68 130.41 10.81
2014-04-30 467.61 42.18 125.10 9.83
2014-01-31 452.64 40.92 120.77 9.59
2013-10-31 440.57 40.24 115.25 9.29
2013-07-31 422.94 38.63 112.78 9.32
2013-04-30 408.57 38.06 109.42 9.47
2013-01-31 401.65 37.22 107.41 9.29
2012-10-31 392.91 34.07 106.08 9.40
2012-07-31 386.49 30.76 101.85 9.25

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Cantel Medical has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Cantel Medical used its assets more efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • Cantel Medical's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Cantel Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cantel Medical has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CI2 Health

 How is Cantel Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cantel Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cantel Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cantel Medical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cantel Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cantel Medical Company Filings, last reported 3 months ago.

DB:CI2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 641.60 237.58 71.03
2018-10-31 622.36 194.94 64.03
2018-07-31 608.87 197.30 94.10
2018-04-30 601.31 169.00 51.92
2018-01-31 586.48 160.00 39.98
2017-10-31 542.58 168.00 37.22
2017-07-31 523.93 126.00 36.58
2017-04-30 503.88 145.32 30.87
2017-01-31 483.16 149.32 24.35
2016-10-31 460.42 161.41 26.14
2016-07-31 454.37 116.00 28.37
2016-04-30 447.64 132.84 25.50
2016-01-31 427.45 133.98 21.60
2015-10-31 417.63 148.07 31.13
2015-07-31 406.63 78.50 31.72
2015-04-30 394.22 92.18 25.37
2015-01-31 380.36 96.21 24.09
2014-10-31 375.70 93.55 29.71
2014-07-31 365.25 80.57 31.78
2014-04-30 354.44 64.60 24.47
2014-01-31 342.02 74.61 19.71
2013-10-31 330.43 82.15 28.45
2013-07-31 321.13 95.16 34.08
2013-04-30 307.96 105.24 30.67
2013-01-31 298.00 107.23 26.83
2012-10-31 284.60 80.30 27.87
2012-07-31 275.94 90.34 30.19
  • Cantel Medical's level of debt (37%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (21.8% vs 37% today).
  • Debt is well covered by operating cash flow (42.3%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 17.2x coverage).
X
Financial health checks
We assess Cantel Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cantel Medical has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CI2 Dividends

 What is Cantel Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.3%
Current annual income from Cantel Medical dividends. Estimated to be 0.34% next year.
If you bought €2,000 of Cantel Medical shares you are expected to receive €6 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Cantel Medical's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.45%).
  • Cantel Medical's dividend is below the markets top 25% of dividend payers in Germany (3.8%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CI2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CI2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-07-31
2022-07-31
2021-07-31
2020-07-31 0.25 1.00
2019-07-31 0.20 1.00
DB:CI2 Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-03-01 0.200 0.296
2019-02-28 0.200 0.271
2018-12-19 0.200 0.254
2018-06-27 0.170 0.190
2018-06-01 0.170 0.170
2018-05-31 0.170 0.156
2018-03-08 0.170 0.146
2017-11-01 0.170 0.160
2017-06-29 0.140 0.169
2017-06-08 0.140 0.182
2017-03-29 0.140 0.187
2017-03-09 0.140 0.181
2016-10-14 0.140 0.178
2016-06-16 0.120 0.166
2016-06-09 0.120 0.165
2016-06-08 0.120 0.163
2016-03-10 0.120 0.174
2015-10-16 0.120 0.196
2015-06-18 0.100 0.188
2015-06-09 0.100 0.192
2015-03-12 0.100 0.212
2014-11-07 0.100 0.232
2014-06-19 0.090 0.249
2014-06-09 0.090 0.255
2014-06-05 0.090 0.256
2014-03-12 0.090 0.270
2014-03-11 0.090 0.276
2013-10-16 0.090 0.265
2013-09-30 0.073 0.227
2013-09-26 0.073 0.237
2013-06-20 0.074 0.286
2013-06-10 0.073 0.323
2013-06-06 0.073 0.319
2013-03-12 0.073 0.351
2013-03-07 0.073 0.357
2012-12-10 0.073 0.354
2012-12-06 0.073 0.380
2012-11-02 0.073 0.417
2012-10-15 0.062 0.363
2012-10-11 0.062 0.369
2012-06-15 0.062 0.351
2012-06-11 0.062 0.363
2012-06-07 0.067 0.398
2012-03-12 0.062 0.408
2012-03-08 0.067 0.449
2011-10-21 0.062 0.490
2011-10-14 0.053 0.518
2011-10-13 0.053 0.527
2011-06-17 0.053 0.505
2011-06-09 0.053 0.491
2011-06-08 0.053 0.495
2011-03-11 0.053 0.477
2011-03-09 0.053 0.470
2010-12-10 0.053 0.541
2010-12-09 0.053 0.543
2010-10-21 0.053 0.595
2010-06-09 0.044 0.628
2010-06-08 0.044 0.599
2009-12-17 0.044 0.511

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cantel Medical is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Cantel Medical is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Cantel Medical's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Cantel Medical's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • No need to calculate the sustainability of Cantel Medical's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Cantel Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cantel Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cantel Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CI2 Management

 What is the CEO of Cantel Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
George Fotiades
COMPENSATION $283,693
AGE 64
TENURE AS CEO 0.2 years
CEO Bio

Mr. George L. Fotiades has been President and Chief Executive Officer at Cantel Medical Corp. since March 5, 2019. He is an Operating Partner at FAPI focused on Pharma Services / Medical Technology. Mr. George L. Fotiades has been an Independent Director of ProLogis, Inc. since November 2011 and Cantel Medical Corp. since May 2008. He was an Operating Partner of Diamond Castle Holdings, LLC and served as its Chairman of Healthcare from April 2007 to April 2016. He served as an Operating Partner at Five Arrows Capital Partners (Rothschild Merchant Banking). Mr. Fotiades joined the Diamond Castle Holdings in 2007. He served as Member - Office of the Chairman at Cantel Medical Corp. since March 2009. He has more than 30 years of senior-level operating experience at businesses in a variety of industry sub-segments, including Cardinal Health, Warner-Lambert, senior positions at Bristol-Myers Squibb, Wyeth and Procter & Gamble Co. He served as the President and Chief Operating Officer at Catalent Pharma Solutions, Inc. from February 3, 2004 to April 2006. Mr. Fotiades served as an Executive Vice President at Catalent Pharma Solutions, Inc., since November 2000. He served as an Executive Vice President, President and Chief Operating Officer at Pharmaceutical Technologies and Services of Catalent Pharma Solutions, Inc. from November 2000 to December 2002 and served as the President and Chief Executive Officer at Life Sciences Products and Services from December 12, 2002 to February 2004. Mr. Fotiades served as an Executive Vice President and Group President at Catalent Pharma Solutions, Inc. from August 1998 to October 2000 and President from January 1998 to August 1998; and Group President of Americas and Asia Pacific from June 1996 to January 1998. From 1996 to 1998, he served as President and Chief Operating Officer of Catalent Pharma Solutions, Inc., which was merged into Catalent Pharma Solutions, Inc. in August 1998 and also served as an Executive Vice President and Group President of the Americas & Asia Pacific from June 1996 to January 1998. Mr. Fotiades served in a variety of executive roles such as the President at Warner Wellcome Consumer Heathcare division of the Warner-Lambert Company from January 1994 to December 1995 and President of Consumer Health Products Group from November 1992 to December 1993. He served as the President of Consumer Products- Japan division of Bristol-Myers Squibb Company from January 1992 to November 1992 and as a Senior Vice President and General Manager of the Clairol U.S. Retail Products division from January 1991 to January 1992. He serves as an Executive Chairman of YORK Label, Inc. Mr. Fotiades served as Non-Executive Chairman of Catalent Pharma Solutions, Inc from June 2007 to February 10, 2010. He had been Vice Chairman of Cantel Medical Corporation since March 2009 until March 2019. He serves as a Director of Managed Health Care Associates, Inc., Suture Express, Inc., and York Label. He has been an Independent Director at AptarGroup, Inc. since May 2011 and its Chairman since May 2, 2018. He served as a Director of Catalent Pharma Solutions, Inc. from January 1998 to February 10, 2010 and Alberto-Culver Company from December 1, 2006 to May 2011. Mr. Fotiades was previously the President and Chief Operating Officer of Cardinal Health, Inc. and also served as President and Chief Executive Officer of Cardinal Health, Inc.’s Pharmaceutical Technologies and Services segment. Mr. Fotiades holds Bachelor of Arts from Amherst College and an M.B.A. and M.M. from the Kellogg School of Management at Northwestern University.

CEO Compensation
  • George's compensation has been consistent with company performance over the past year.
  • George's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cantel Medical management team in years:

2.4
Average Tenure
54.5
Average Age
  • The tenure for the Cantel Medical management team is about average.
Management Team

Mark Diker

TITLE
Chairman and Member of Office of the Chairman
COMPENSATION
$857K
AGE
83

George Fotiades

TITLE
President
COMPENSATION
$284K
AGE
64
TENURE
0.2 yrs

Peter Clifford

TITLE
Executive VP
COMPENSATION
$1M
AGE
48

Eric Nodiff

TITLE
Executive VP
COMPENSATION
$1M
AGE
61
TENURE
14.3 yrs

Seth Yellin

TITLE
Executive VP of Strategy & Corporate Development and Member of Office of the Chairman
COMPENSATION
$966K
AGE
44
TENURE
2.7 yrs

Shaun Blakeman

TITLE
Senior VP & CFO

Brian Capone

TITLE
Senior VP
AGE
43
TENURE
2.1 yrs

Daniel Khalili

TITLE
Chief Technology Officer

Matt Micowski

TITLE
Vice President of Corporate FP&A and Investor Relations

Milicent Brooks

TITLE
Head of Corporate Communications
Board of Directors Tenure

Average tenure and age of the Cantel Medical board of directors in years:

8.2
Average Tenure
66
Average Age
  • The tenure for the Cantel Medical board of directors is about average.
Board of Directors

Mark Diker

TITLE
Chairman and Member of Office of the Chairman
COMPENSATION
$857K
AGE
83
TENURE
33.1 yrs

George Fotiades

TITLE
President
COMPENSATION
$284K
AGE
64
TENURE
10.2 yrs

Alan Batkin

TITLE
Presiding Independent Director
COMPENSATION
$155K
AGE
73
TENURE
14.4 yrs

Ann Berman

TITLE
Independent Director
COMPENSATION
$153K
AGE
66
TENURE
8.2 yrs

Mark Diker

TITLE
Director
COMPENSATION
$115K
AGE
52
TENURE
11.6 yrs

Peter Pronovost

TITLE
Independent Director
COMPENSATION
$25K
AGE
53
TENURE
1.5 yrs

Laura Forese

TITLE
Independent Director
COMPENSATION
$124K
AGE
57
TENURE
4.2 yrs

Ronnie Myers

TITLE
Director
COMPENSATION
$124K
AGE
66
TENURE
2.9 yrs

Tony Evnin

TITLE
Director
COMPENSATION
$116K
AGE
77
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • Cantel Medical insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Apr 19 Sell Lawrence Conway Individual 05. Apr 19 05. Apr 19 -800 €59.74 €-47,795
29. Mar 19 Sell Brian Capone Individual 27. Mar 19 27. Mar 19 -70 €58.74 €-4,112
26. Mar 19 Sell Ronnie Myers Individual 22. Mar 19 22. Mar 19 -261 €58.90 €-15,372
18. Jan 19 Sell Ronnie Myers Individual 15. Jan 19 15. Jan 19 -1,006 €69.89 €-70,312
01. Oct 18 Sell Eric Nodiff Individual 28. Sep 18 28. Sep 18 -2,906 €79.97 €-232,384
09. Jul 18 Sell Ronnie Myers Individual 06. Jul 18 06. Jul 18 -261 €81.42 €-21,250
X
Management checks
We assess Cantel Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cantel Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CI2 News

Simply Wall St News

CI2 Company Info

Description

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company’s Endoscopy segment offers automated endoscope reprocessing systems; infectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets, transport systems, and mobile medical carts; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Water Purification and Filtration segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratory and pharmaceutical, food and beverage, and commercial industrial customers. The company’s Healthcare Disposables segment offers biological indicators, chemical integrators, sterilization pouches, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, amalgam separators, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company’s Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.

Details
Name: Cantel Medical Corp.
CI2
Exchange: DB
Founded: 1963
$2,464,785,987
41,522,675
Website: http://www.cantelmedical.com
Address: Cantel Medical Corp.
150 Clove Road,
9th Floor,
Little Falls,
New Jersey, 07424,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE CMD Common Stock New York Stock Exchange US USD 28. Jan 1976
DB CI2 Common Stock Deutsche Boerse AG DE EUR 28. Jan 1976
Number of employees
Current staff
Staff numbers
2,693
Cantel Medical employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/18 21:46
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/13
Last earnings filing: 2019/03/01
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.